About this trial
The aim of the present study is to determine outcome predictors in children who were diagnosed as acute disseminated encephalomyelitis (ADEM).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Children aged from 6 months old to 18 years.
Presence of clinical signs of acute encephalopathy with multifocal neurological deficits.
MRI findings suggestive of demyelinating lesions.
Disqualifiers
Pediatric patients diagnosed who were as multiple sclerosis.
Pediatric patients with clinical signs and radiological findings suggestive of neuromyelitis optica spectrum disorder.
Pediatric patients with infectious encephalitis.
Pediatric patients with metabolic or genetic neurological disorders
Trial population
Children aged from 6 months old to 18 years. 2. Presence of clinical signs of acute encephalopathy with multifocal neurological deficits
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Proportion of Patients Achieving Complete Recovery Assessed by the Modified Rankin Scale (mRS)
Functional disability and recovery are assessed using the Modified Rankin Scale (mRS), a validated 7-point scale ranging from 0 to 6. A score of 0 indicates no symptoms at all, 5 indicates severe disability (bedridden, requiring constant care), and 6 indicates death. For this study, complete recovery is defined as achieving an mRS score of 0 or 1 (no significant disability). This measure reports the percentage of participants who meet this specific recovery criteria.
Secondary outcomes
Incidence of Disease Relapse
This measure evaluates the percentage of participants who experience a new inflammatory demyelinating event. As per the study protocol, a relapse is specifically defined as the onset of a new neurological event occurring more than 3 months after the patient's initial clinical recovery.
Incidence of Residual Neurological Deficits
This measure reports the proportion of participants who exhibit long-term cognitive or motor sequelae following the acute disease phase. The presence or absence of these residual deficits is determined through standard clinical neurological examinations conducted during outpatient follow-up.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: